Myalept
Payments companies reported to CMS as associated with Myalept. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Myalept, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Myalept
These are the largest totals companies reported as associated with Myalept. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Dhaval Desai | Corona, CA | Interventional Cardiology | $67,086.25 |
| Lindsay Fourman | Boston, MA | Endocrinology, Diabetes & Metabolism | $11,743.26 |
| Nivedita Patni | Dallas, TX | Pediatric Endocrinology | $11,639.29 |
| Tamer Yacoub | Fall River, MA | Endocrinology, Diabetes & Metabolism | $10,950.97 |
| Abhimanyu Garg | Dallas, TX | Endocrinology, Diabetes & Metabolism | $10,001.07 |
| Elif Oral | Ann Arbor, MI | Endocrinology, Diabetes & Metabolism | $9,091.36 |
| Daniel Soffer | Media, PA | Internal Medicine | $4,705.00 |
| Kathleen Wyne | Columbus, OH | Endocrinology, Diabetes & Metabolism | $3,251.84 |
| William Alexander | Cary, NC | Infectious Disease | $2,635.00 |
| Ashley Shoemaker | Nashville, TN | Pediatric Endocrinology | $1,675.00 |
Prescribed Myalept?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.